Federal Register / Vol. 72, No. 57 / Monday, March 26, 2007 / Notices 14125 

identify positively botulinum DNA 

samples in a test of botulinum and nonbotulinum clostridia species then to 

determine the toxin type. The diagnostic 

testing described by the subject 

technology requires significantly less 

time than the current gold standard 

diagnostic test. 

Applications: (1) Universal diagnostic 

test for C. botulinum; (2) Diagnostic test 

for C. botulinum capable of detecting all 

seven toxin types; (3) Combination 

diagnostic. 

Development Status: Fully developed. 

Inventors: Daniel C. Douek (VRC/ 

NIAID) et al. 

Patent Status: U.S. Provisional 

Application No. 60/884,539 filed 11 Jan 

2007 (HHS Reference No. E–046–2007/ 

0–US–01). 

Licensing Status: Available for nonexclusive or exclusive licensing. 

Licensing Contact: Susan Ano, Ph.D.; 

301/435–5515; anos@mail.nih.gov. 

Methods and Compositions for 

Protecting Cells From UltrasoundMediated Cytolysis 

Description of Invention: Available for 

licensing and commercial development 

are methods for protecting cells from 

ultrasound-mediated cytolysis. The in 

vitro exposure of cells to ultrasound and 

the therapeutic uses of ultrasound (e.g., 

sonoporation, thrombolysis, HIFU, 

sonophoresis, acoustic hemostasis) may 

induce changes in tissue state, including 

apoptosis and cytolysis, through 

thermal effects (e.g., hyperthermia), 

mechanical effects (e.g., acoustic 

cavitation or through radiation force, 

acoustic streaming and other ultrasound 

induced forces), and chemical effects 

(via sonochemistry or by the activation 

of solutes by sonoluminescence). 

Ultrasound exposure conditions in these 

biomedical and in biological processes 

(e.g. ultrasound bioreactors) are limited 

by the need to increase the beneficial 

effects of ultrasound, while at the same 

time limiting the detrimental effects, 

such as apoptosis and cytolysis. 

Accordingly, the protecting molecules 

used to carry out the methods of the 

invention possess the ability to protect 

cells against ultrasound mediated 

cytolysis, without hindering ultrasound 

induced physical effects that could be 

utilized to create beneficial effects. The 

protecting solutes are surface active and 

possess at least one ‘‘carbohydrate unit’’

as described. The solutes include, but 

are not limited to: alkyl-b-Dthioglucopyranoside, alkyl-b-Dthiomaltopyranoside, alkyl-b-Dgalactopyranoside, alkyl-b-Dthiogalactopyranoside, or alkyl-b-Dmaltrioside, hexyl-b-D-glucopyranoside, 

heptyl-b-D-glucopyranoside, octyl-b-Dglucopyranoside, nonyl-b-Dglucopyranoside, hexyl-b-Dmaltopyranoside, n-octyl-b-Dmaltopyranoside, n-octyl-b-Dthioglucopyranoside, 2-propyl-1-pentylb-D-maltopyranoside, methyl-6-O-(Nheptylcarbamoyl)-a-D-glucopyranoside, 

3-cyclohexyl-1-propyl-b-D-glucoside, 6- 

O-methyl-n-heptylcarboxyl-a-Dglucopyranoside. 

Inventors: Joe Z. Sostaric (NCI), Peter 

Riesz (NCI), et al. 

Publications: 

1. Joe Z. Sostaric, Norio Miyoshi, 

Peter Riesz, William G. DeGraff and 

James B. Mitchell. n-Alkyl 

glucopyranosides completely inhibit 

ultrasound-induced cytolysis. Free 

Radic Biol Med. 2005 Dec 

15;39(12):1539–1548. 

2. Joe Z. Sostaric, Norio Miyoshi, 

Peter Riesz, William G. Degraff and 

James B. Mitchell. Complete inhibition 

of ultrasound-induced cytolysis in the 

presence of inertial cavitation. AIP Conf 

Proc. 2006 May 8;829:39–43. 

Patent Status: PCT Application No. 

PCT/US2005/037912 filed 19 Oct 2005, 

which published as WO 2006/045050 

on 27 Apr 2006; claiming priority to 19 

Oct 2004 (HHS Reference No. E–311–

2004/0–PCT–02). 

Licensing Status: Available for nonexclusive or exclusive licensing. 

Licensing Contact: Michael 

Shmilovich, Esq.; 301/435–5019; 

shmilovm@mail.nih.gov. 

Dated: March 12, 2007. 

Steven M. Ferguson, 

Director, Division of Technology Development 

and Transfer, Office of Technology Transfer, 

National Institutes of Health. 

[FR Doc. E7–5426 Filed 3–23–07; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Heart, Lung, and Blood 

Institute; Notice of Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. Appendix 2), notice 

is hereby given of the following 

meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Heart, Lung, 

and Blood Institute Special Emphasis Panel, 

Shared Resource Grant (R24). 

Date: April 23, 2007. 

Time: 1 p.m. to 4 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6701 

Rockledge Drive, Bethesda, MD 20892, 

(Telephone Conference Call). 

Contact Person: Keary A. Cope, PhD, 

Scientific Review Administrator, Review 

Branch/DERA, National Heart, Lung, and 

Blood Institute, 6701 Rockledge Drive, Room 

7190, Bethesda, MD 20892–7924, 301–435–

2222, copeka@mail.nih.gov. 

(Catalogue of Federal Domestic 

Assistance Program Nos. 93.233, 

National Center for Sleep Disorders 

Research; 93.837, Heart and Vascular 

Diseases Research; 93.838, Lung 

Diseases Research; 3.839, Blood 

Diseases and Resources Research, 

National Institutes of Health, HHS) 

Dated: March 12, 2007. 

Anna Snouffer, 

Acting Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 07–1450 Filed 3–23–07; 8:45 am] 

BILLING CODE 4140–01–M 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Heart, Lung, and Blood 

Institute; Notice of Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. Appendix 2), notice 

is hereby given of the following 

meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Heart, Lung, 

and Blood Institute Special Emphasis Panel, 

Lung Disease Research Project. 

Date: April 12, 2007. 

Time: 2:30 p.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6701 

Rockledge Drive, Bethesda, MD 20892, 

(Telephone Conference Call). 


cprice-sewell on PROD1PC66 with NOTICES